| 06/11/2026 4:44 PM | Biogen (875045) Issuer Mantas Jesus B (1777331) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/11/2026 4:46 PM | Biogen (875045) Issuer Rowinsky Eric K (1318886) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/11/2026 4:47 PM | Biogen (875045) Issuer SHERWIN STEPHEN A (1079462) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/11/2026 4:50 PM | Biogen (875045) Issuer HAWKINS WILLIAM A (1106508) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/11/2026 4:32 PM | Biogen (875045) Issuer Patolawala Monish D (1815253) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/11/2026 4:34 PM | Biogen (875045) Issuer LANGER SUSAN (1982640) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/11/2026 4:09 PM | Biogen (875045) Issuer Freire Maria C (1547999) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/11/2026 4:17 PM | Biogen (875045) Issuer Minor Lloyd (2038687) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/11/2026 4:21 PM | Biogen (875045) Issuer Pangalos Menelas N (2001873) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/10/2026 3:54 PM | Biogen (875045) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/10/2026 3:49 PM | Biogen (875045) Filer | Form 8-K/A | |
Get the Latest News and Ratings for BIIB and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter.
|
| 06/05/2026 9:13 AM | Biogen (875045) Subject FMR LLC (315066) Filed by | Form SCHEDULE 13G/A | |
| 05/14/2026 3:36 PM | Apellis Pharmaceuticals, Inc. (1492422) Subject Biogen (875045) Filed by | Form SCHEDULE 13D/A | |
| 05/14/2026 7:31 AM | Biogen (875045) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/14/2026 6:53 AM | Apellis Pharmaceuticals, Inc. (1492422) Subject Biogen (875045) Filed by | Form SC TO-T/A | |
| 05/12/2026 6:06 AM | Apellis Pharmaceuticals, Inc. (1492422) Subject Biogen (875045) Filed by | Form SC TO-T/A | |
| 05/06/2026 10:00 AM | Biogen (875045) Subject FMR LLC (315066) Filed by | Form SCHEDULE 13G/A | |
| 04/29/2026 4:00 PM | Biogen (875045) Subject VANGUARD CAPITAL MANAGEMENT LLC (2100119) Filed by | Form SCHEDULE 13G | |
| 04/29/2026 5:40 AM | Biogen (875045) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 04/29/2026 5:05 AM | Biogen (875045) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 04/28/2026 3:42 PM | Biogen (875045) Filer | Form DEFA14A | |
| 04/28/2026 3:47 PM | Biogen (875045) Filer | Form ARS | |
| 04/28/2026 3:34 PM | Biogen (875045) Filer | Form DEF 14A | |
| 04/14/2026 6:02 AM | Apellis Pharmaceuticals, Inc. (1492422) Subject Biogen (875045) Filed by | Form SC TO-T | |
| 04/07/2026 4:05 PM | Apellis Pharmaceuticals, Inc. (1492422) Subject Biogen (875045) Filed by | Form SC TO-C | |
| 04/06/2026 5:08 PM | Apellis Pharmaceuticals, Inc. (1492422) Subject Biogen (875045) Filed by | Form SCHEDULE 13D | |
| 04/06/2026 5:11 PM | Apellis Pharmaceuticals, Inc. (1492422) Issuer Biogen (875045) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 04/06/2026 5:31 AM | Biogen (875045) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 04/03/2026 4:10 PM | Apellis Pharmaceuticals, Inc. (1492422) Subject Biogen (875045) Filed by | Form SC TO-C | |
| 04/03/2026 3:05 PM | Biogen (875045) Issuer Godbout Sean (2057736) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/31/2026 4:01 PM | Apellis Pharmaceuticals, Inc. (1492422) Subject Biogen (875045) Filed by | Form SC TO-C | |
| 03/31/2026 4:03 PM | Biogen (875045) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/31/2026 4:08 PM | Apellis Pharmaceuticals, Inc. (1492422) Subject Biogen (875045) Filed by | Form SC TO-C | |
| 03/26/2026 3:09 PM | Biogen (875045) Subject VANGUARD GROUP INC (102909) Filed by | Form SCHEDULE 13G/A | |
| 03/11/2026 4:28 PM | Biogen (875045) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 02/17/2026 7:10 PM | Biogen (875045) Issuer Grogan Jane (1995547) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/17/2026 7:11 PM | Biogen (875045) Issuer Izzar Rachid (1875506) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/17/2026 7:12 PM | Biogen (875045) Issuer Keeney Adam (1973607) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/17/2026 7:14 PM | Biogen (875045) Issuer Kramer Robin (1609222) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/17/2026 7:16 PM | Biogen (875045) Issuer Murphy Nicole (1910644) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/17/2026 7:17 PM | Biogen (875045) Issuer Singhal Priya (1769608) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (Ad) Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain. Get the name and ticker of Louis Navellier's #1 AI stock free |
| 02/17/2026 7:18 PM | Biogen (875045) Issuer Viehbacher Christopher (1774478) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/17/2026 7:05 PM | ALEXANDER SUSAN H (1263839) Reporting Biogen (875045) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/17/2026 7:07 PM | Biogen (875045) Issuer Godbout Sean (2057736) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/17/2026 7:09 PM | Biogen (875045) Issuer Gregory Ginger (1545716) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/11/2026 4:07 PM | Biogen (875045) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 02/10/2026 3:55 PM | ALEXANDER SUSAN H (1263839) Reporting Biogen (875045) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/10/2026 3:56 PM | Biogen (875045) Issuer Godbout Sean (2057736) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/10/2026 3:58 PM | Biogen (875045) Issuer Gregory Ginger (1545716) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/10/2026 3:59 PM | Biogen (875045) Issuer Grogan Jane (1995547) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/10/2026 4:00 PM | Biogen (875045) Issuer Izzar Rachid (1875506) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/10/2026 4:01 PM | Biogen (875045) Issuer Keeney Adam (1973607) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/10/2026 4:02 PM | Biogen (875045) Issuer Kramer Robin (1609222) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/09/2026 9:14 AM | Biogen (875045) Subject Singhal Priya (1769608) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 02/06/2026 6:36 AM | Biogen (875045) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 02/06/2026 5:55 AM | Biogen (875045) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 02/05/2026 12:16 PM | Biogen (875045) Subject FMR LLC (315066) Filed by | Form SCHEDULE 13G | |
| 02/02/2026 10:10 AM | Biogen (875045) Subject Singhal Priya (1769608) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 11/13/2025 7:28 PM | Biogen (875045) Subject PRIMECAP MANAGEMENT CO/CA/ (763212) Filed by | Form SCHEDULE 13G/A | |
| 11/10/2025 7:15 AM | Biogen (875045) Subject STATE STREET CORP (93751) Filed by STATE STREET CORP (93751) Filed by | Form SCHEDULE 13G | |
| 10/30/2025 5:31 AM | Biogen (875045) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 10/30/2025 5:13 AM | Biogen (875045) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 10/14/2025 3:19 PM | Biogen (875045) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 10/06/2025 12:00 PM | Biogen (875045) Issuer Godbout Sean (2057736) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/02/2025 4:56 PM | Biogen (875045) Issuer Singhal Priya (1769608) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/02/2025 11:54 AM | Biogen (875045) Subject Singhal Priya (1769608) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/31/2025 5:05 AM | Biogen (875045) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 07/31/2025 5:13 AM | Biogen (875045) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/30/2025 4:56 PM | Biogen (875045) Filed by Sage Therapeutics, Inc. (1597553) Subject | Form SCHEDULE 13D/A | |
| 07/21/2025 8:18 PM | Biogen (875045) Filed by Sage Therapeutics, Inc. (1597553) Subject | Form SCHEDULE 13D/A | |